Last C$0.67 CAD
Change Today +0.01 / 1.52%
Volume 10.4K
As of 3:53 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

aeterna zentaris inc (AEZ) Snapshot

Open
C$0.65
Previous Close
C$0.66
Day High
C$0.67
Day Low
C$0.65
52 Week High
09/2/14 - C$1.68
52 Week Low
11/19/14 - C$0.55
Market Cap
43.9M
Average Volume 10 Days
29.1K
EPS TTM
C$-0.62
Shares Outstanding
65.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AETERNA ZENTARIS INC (AEZ)

Related News

No related news articles were found.

aeterna zentaris inc (AEZ) Related Businessweek News

No Related Businessweek News Found

aeterna zentaris inc (AEZ) Details

Aeterna Zentaris Inc., a specialty biopharmaceutical company, is focused on developing and commercializing novel treatments in oncology and endocrinology. The company’s product pipeline includes MACRILEN, for which a New Drug Application is under review by the FDA as an oral product used for evaluating adult growth hormone deficiency. MACRILEN is also investigated in a Phase 2A clinical trial to treat cancer-induced cachexia. Its product pipeline also comprises zoptarelin doxorubicin, which is in the ZoptEC (zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent, or metastatic endometrial cancer. In addition, the company’s preclinical product candidates in oncology include AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136; and disorazol Z product candidates, such as AEZS-137 and AEZS-138. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.

Founded in 1991

aeterna zentaris inc (AEZ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $328.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $331.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $122.0K
Compensation as of Fiscal Year 2013.

aeterna zentaris inc (AEZ) Key Developments

Aeterna Zentaris Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Aeterna Zentaris Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

Glancy Binkow & Goldberg LLP Announces Expanded Class Period in the Shareholder Lawsuit Against Aeterna Zentaris Inc

Glancy Binkow & Goldberg LLP announced that a class action complaint has been filed with an expanded Class Period in the shareholder lawsuit pending in the United States District Court for the District of New Jersey against Aeterna Zentaris Inc. The complaint alleges violations of federal securities laws and asserts claims on behalf of purchasers of Aeterna securities between April 2, 2012 and November 6, 2014, inclusive. Aeterna is a specialty biopharmaceutical company engaged in the development and commercialization of novel treatments in oncology and endocrinology. The Company is developing macimorelin’ an orally active small molecule that stimulates the secretion of growth hormone as a treatment for Adult Growth Hormone Deficiency. The lawsuit alleges that defendants misrepresented or failed to disclose that: the planned analysis of macimorelin's pivotal clinical trial failed to meet its primary efficacy endpoint pursuant to the Special Protocol Assessment agreement letter between the Company and the FDA; insufficient data existed to confirm that the patients in the clinical trial were accurately diagnosed with Adult Growth Hormone Deficiency; a serious cardiac event could have been attributed to macimorelin; (4) as a result, the FDA would not approve the New Drug Application for macimorelin in its present form; and, the Company's statements about its business, operations and prospects, including statements about macimorelin's prospects for FDA approval, were materially false and misleading and/or lacked a reasonable basis.

Aeterna Zentaris Announces Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer

Aeterna Zentaris Inc. announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research. The article outlines data previously disclosed in June 2013 at the American Society of Clinical Oncology's Annual Meeting, which demonstrated the compound's safety profile and promising anti-tumor activity in heavily pre-treated men with castration- and taxane-resistant prostate cancer. Luteinizing hormone-releasing hormone receptors are expressed on the cell membrane of many tumors, including prostate cancer. This Phase I study with zoptarelin doxorubicin which targets these LHRH receptors, determined the maximum tolerated dose of this agent in men with taxane- and castration-resistant PC while providing additional information on its safety profile and efficacy. Zoptarelin doxorubicin was administered as an intravenous infusion every 21 days until progression or unacceptable toxicity in cohorts of 3 or 6 patients until the maximum tolerated dose was reached. The MTD of zoptarelin doxorubicin in this cohort was 210 mg/m2, which was lower than that seen in a Phase I study conducted in women with endometrial or ovarian cancers. The dose limiting toxicity was persistent neutropenia. Three patients had a prostate-specific antigen response with an additional 10 patients maintaining PSA stable disease. Of the 10 patients evaluable by RECIST criteria, 9 achieved stable disease. These findings show that zoptarelin doxorubicin has an acceptable safety profile and a signal of efficacy, lowering PSA in heavily pretreated patients with prostate cancer, and that internalization of zoptarelin doxorubicin in PC circulating tumor cells may be a viable pharmacodynamic marker. This is a single-arm Simon Optimum design Phase 2 study of zoptarelin doxorubicin involving up to 37 patients with pre treated castration-and taxane-resistant prostate cancer, using the dose selected (210 mg/m2) in the Phase 1 portion. The primary endpoint is to evaluate the clinical benefit of zoptarelin doxorubicin for these patients. Clinical benefit will be defined as non-progression at 12 weeks with no dose limiting toxicity or other toxicity requiring termination of treatment. More information on the current Phase 2 portion of the trial is available at this link: NCT01240629.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEZ:CN C$0.67 CAD +0.01

AEZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEZ.
View Industry Companies
 

Industry Analysis

AEZ

Industry Average

Valuation AEZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETERNA ZENTARIS INC, please visit www.aezsinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.